COLUMBUS, Ohio – Dr. Matthew D. Ringel, a physician and researcher at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) who specializes in thyroid and endocrine tumors, has been awarded the American Thyroid Association’s 2009 Van Meter Award. The Van Meter Award is the association’s oldest award, established in 1930, and presented to an investigator age 45 or under who has made outstanding contributions to thyroid disease research.
Ringel’s research focuses on the pathways in the development and spread of thyroid and endocrine tumors. He has authored more than 90 original articles, book chapters and review articles.
Ringel is a professor in the division of endocrinology, diabetes and metabolism at The Ohio State University with joint appointments in the division of medical oncology and the department of molecular virology, immunology, and genetics. He received his medical degree from the Pennsylvania State University College of Medicine in 1991 and completed his Internal Medicine and Endocrinology training at Georgetown University and Johns Hopkins University, respectively.
His past honors include an “Outstanding Reviewer Award: Journal of Clinical Endocrinology and Metabolism” in 2005. He has served or is currently serving on the editorial boards of Thyroid, Endocrine Reviews, Journal of Clinical Endocrinology, and Endocrine-Related Cancer.
The American Thyroid Association is the lead organization in promoting thyroid health and understanding thyroid biology.
The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top 20 cancer hospitals in the nation, The James (www.jamesline.com) is the 180-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only five centers in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.# # #
Medical Center Communications